Mining the Genome: Big Science as Big Business -- A special report.; PROFITS AND ETHICS CLASH IN RESEARCH ON GENETIC CODING
The Human Genome Project, an international quest to spell out the precise sequence of the three billion letters in the human genetic code, is still more than a decade from completion. But in a rapid blurring of big science and big business, the effort has already created its first millionaires. One is J. Craig Venter, who as a Federal employee at the National Institutes of Health developed crucial technology for spelling out -- or "sequencing" -- long strands of genetic code. Then, a little more than a year ago, he left to join a venture to commercialize the technology. Now, even before they have a product, Dr. Venter and his backers have raised millions of dollars by selling public shares of stock in their venture, Human Genome Sciences Inc., of Bethesda, Md. Differing Perspectives Depending on one's perspective, Dr. Venter and his company typify the ideal link between Government-supported basic science and the entrepreneurial verve necessary for seeing that the fruits of the Human Genome Project make their way into the medical marketplace. But some scientists are uneasy -- ethically and professionally -- with the idea of their colleagues profiting from the research for which the Government has paid.
